Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers
Immune checkpoint inhibitor (ICI) treatment has the potential to induce durable disease remission. However, the current combined positive score (CPS) is insufficient accurate for predicting which patients will benefit from it. In the present study, a real-world retrospective study was conducted on 5...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136448574554112 |
|---|---|
| author | Ruihua Fang Yi Chen Bixue Huang Zhangfeng Wang Xiaolin Zhu Dawei Liu Wei Sun Lin Chen Minjuan Zhang Kexing Lyu Wenbin Lei |
| author_facet | Ruihua Fang Yi Chen Bixue Huang Zhangfeng Wang Xiaolin Zhu Dawei Liu Wei Sun Lin Chen Minjuan Zhang Kexing Lyu Wenbin Lei |
| author_sort | Ruihua Fang |
| collection | DOAJ |
| description | Immune checkpoint inhibitor (ICI) treatment has the potential to induce durable disease remission. However, the current combined positive score (CPS) is insufficient accurate for predicting which patients will benefit from it. In the present study, a real-world retrospective study was conducted on 56 patients of HNSCC who received ICI treatment. Then the treatment that patient received and levels of pre-treatment blood inflammatory markers (NLR, MLR and PLR) were identified to develop a model for predicting immunotherapy response. Notably, the model achieved an area under the curve (AUC) of 0.877 (95 % CI 0.769–0.985) , providing a larger net benefit than the CPS marker (AUC=0.614, 95 % CI 0.466–0.762). Furthermore, the internal validation of the prediction model showed a C-index of 0.835. Patients with high score of the model would get improved PFS than those with low score. Therefore, the prediction model for patients with local advanced or R/M HNSCC receiving ICI treatment, which represented an better efficient prediction of immunotherapy response than CPS marker. |
| format | Article |
| id | doaj-art-2283b380ccc24ba2bacd6e9469b7e44d |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-2283b380ccc24ba2bacd6e9469b7e44d2024-12-09T04:27:17ZengElsevierTranslational Oncology1936-52332025-01-0151102222Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markersRuihua Fang0Yi Chen1Bixue Huang2Zhangfeng Wang3Xiaolin Zhu4Dawei Liu5Wei Sun6Lin Chen7Minjuan Zhang8Kexing Lyu9Wenbin Lei10Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR China; Corresponding authors at: Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou 510080, Guangdong, PR China.Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR China; Corresponding authors at: Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou 510080, Guangdong, PR China.Immune checkpoint inhibitor (ICI) treatment has the potential to induce durable disease remission. However, the current combined positive score (CPS) is insufficient accurate for predicting which patients will benefit from it. In the present study, a real-world retrospective study was conducted on 56 patients of HNSCC who received ICI treatment. Then the treatment that patient received and levels of pre-treatment blood inflammatory markers (NLR, MLR and PLR) were identified to develop a model for predicting immunotherapy response. Notably, the model achieved an area under the curve (AUC) of 0.877 (95 % CI 0.769–0.985) , providing a larger net benefit than the CPS marker (AUC=0.614, 95 % CI 0.466–0.762). Furthermore, the internal validation of the prediction model showed a C-index of 0.835. Patients with high score of the model would get improved PFS than those with low score. Therefore, the prediction model for patients with local advanced or R/M HNSCC receiving ICI treatment, which represented an better efficient prediction of immunotherapy response than CPS marker.http://www.sciencedirect.com/science/article/pii/S1936523324003486Head and neck squamous cell carcinomasImmunotherapyResponse ratePrediction modelProgression-free survival |
| spellingShingle | Ruihua Fang Yi Chen Bixue Huang Zhangfeng Wang Xiaolin Zhu Dawei Liu Wei Sun Lin Chen Minjuan Zhang Kexing Lyu Wenbin Lei Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers Translational Oncology Head and neck squamous cell carcinomas Immunotherapy Response rate Prediction model Progression-free survival |
| title | Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| title_full | Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| title_fullStr | Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| title_full_unstemmed | Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| title_short | Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| title_sort | predicting response to pd 1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers |
| topic | Head and neck squamous cell carcinomas Immunotherapy Response rate Prediction model Progression-free survival |
| url | http://www.sciencedirect.com/science/article/pii/S1936523324003486 |
| work_keys_str_mv | AT ruihuafang predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT yichen predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT bixuehuang predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT zhangfengwang predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT xiaolinzhu predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT daweiliu predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT weisun predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT linchen predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT minjuanzhang predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT kexinglyu predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers AT wenbinlei predictingresponsetopd1inhibitorsinheadandnecksquamouscellcarcinomasusingperipheralbloodinflammatorymarkers |